Routinely collected health data on 10-year genitourinary and gastrointestinal morbidity after ultra-hypofractionated versus conventionally fractionated radiotherapy for localised prostate cancer in the randomised, non-inferiority, phase 3 trial HYPO-
The results support the HYPO-RT-PC findings by showing similar morbidity between ultra-hypofractionated and standard radiotherapy. Excess events were estimated to 4-8%, without increased associated mortality.
Authors
- Per Nilsson (ORCID: https://orcid.org/0000-0002-7983-9778)
- Gabriel Adrian (ORCID: https://orcid.org/0000-0001-8837-4696)
- Adalsteinn Gunnlaugsson (ORCID: https://orcid.org/0000-0003-1354-8537)
- Hans Garmo (ORCID: https://orcid.org/0000-0001-7181-7083)
- Anders Widmark (ORCID: https://orcid.org/0000-0001-9845-055X)
- Elisabeth Kjellén
- P. Stattin (ORCID: https://orcid.org/0009-0008-3922-5561)
- Astrid E. Persson (ORCID: https://orcid.org/0009-0003-5205-8773)
Institutions
- Uppsala University Hospital (SE)
- Lund University (SE)
- Skåne University Hospital (SE)
- Umeå University (SE)
Publication Details
- Journal
- Radiotherapy and Oncology
- Published
- 2025-12-11
- DOI
- https://doi.org/10.1016/j.radonc.2025.111323
- Citations
- 1
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.52